The THEMIS trial of Brilinta/Brilique (ticagrelor) in combination with aspirin in patients with coronary artery disease (CAD) and type 2 diabetes with no prior heart attack or stroke will give a modest boost to sales but is unlikely to prevent the product being overtaken by Farxiga in AstraZeneca PLC’s CV portfolio.
AstraZeneca Aiming To Extend Brilinta Use In PCI patients
AstraZeneca PLC’s newer oncology treatments are currently powering its growth, but the company is also looking to its cardiovascular, renal & metabolism (CVRM) portfolio to contribute, and a new study of Brilinta will help.
